PSEN1 A246E

PSEN1 (presenilin-1) is a critical component of gamma-secretase, a multi-protein enzyme complex that cuts other proteins within cell membranes. The A246E mutation, where alanine at position 246 is replaced by glutamic acid, is classified as pathogenic by ClinVar based on multiple expert assessments and has never been observed in healthy population databases (gnomAD), strongly supporting its disease-causing role. This mutation causes autosomal dominant Alzheimer's disease with an average onset age of 49 years (range 40-66), meaning children of carriers have a 50% chance of inheriting the mutation and developing early-onset dementia [1]. The mutation occurs in transmembrane domain 6 (TMD6), one of the nine membrane-spanning segments that anchor presenilin-1 within cellular membranes. This location is near the catalytic center where gamma-secretase performs its cutting function. The A246E mutation impairs the enzyme's processivity—its ability to make sequential cuts—resulting in altered ratios of amyloid-beta peptides. Specifically, it reduces production of shorter Abeta37-40 fragments while increasing longer Abeta42-43 species that aggregate more readily into toxic plaques. Research across multiple PSEN1 mutations shows that lower ratios of short-to-long amyloid-beta fragments correlate strongly with earlier disease onset (R²=0.78), suggesting the cutting efficiency directly influences when symptoms appear. Beyond amyloid pathology, the A246E mutation causes early functional deficits in neurons before plaques form. Studies using induced pluripotent stem cells (iPSCs) from A246E carriers transformed into neurons reveal reduced neuronal excitability—these cells fire electrical signals less readily than healthy neurons [1]. The mutation causes an imbalance between sodium channels (which promote firing) and potassium channels (which inhibit firing), with A246E neurons showing elevated potassium channel activity. The mutation also disrupts neural progenitor cells during brain development, causing premature differentiation, reduced proliferation, and increased cell death through dysregulated Wnt and Notch signaling pathways [2]. These early developmental and functional changes occur independently of amyloid or tau pathology, suggesting multiple disease mechanisms beyond the traditional plaque hypothesis. The AlphaFold2 structure prediction for PSEN1 A246E has an average confidence score of 67.7 out of 100, indicating moderate reliability. This confidence level is typical for multi-pass membrane proteins like presenilin, where the hydrophobic transmembrane regions are challenging to model accurately. While the overall domain architecture and approximate location of TMD6 can be reasonably inferred, the precise atomic positions of amino acids—particularly how the glutamic acid substitution reorients within the membrane environment—should be interpreted cautiously. The low-to-moderate confidence prevents detailed structural comparison with wild-type presenilin or mechanistic interpretation of how the mutation specifically disrupts gamma-secretase's catalytic pocket geometry. Therapeutic implications from this mutation include potential early intervention strategies targeting neuronal excitability deficits through potassium channel modulators or approaches to restore gamma-secretase processivity and normalize amyloid-beta ratios [1]. Since functional neuronal deficits appear before plaque formation, treatments addressing these early electrical and developmental abnormalities might delay symptom onset in presymptomatic carriers identified through genetic testing. The strong correlation between amyloid-beta processing ratios and age of onset suggests that precisely correcting gamma-secretase cutting patterns could have disease-modifying potential, though no A246E-specific therapies currently exist.